OmiCure uses the SOPHiA DDM™ Platform to advance its testing technology
BOSTON, United States and Rolle, Switzerland, December 21, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that OmiCure®, a leading European digital health company, is live on the SOPHiA DDM™ Platform. OmiCure, which works to expand the use of data-driven medicine via its tumor profiling tests, will use SOPHiA GENETICS’ technology to enhance its offerings in support of physicians and patients.
OmiCure, which was launched in November 2019 as a spin-off of Ariana Pharma, provides state-of the-art interpretation tools to oncologists to aid them in the use of precision medicine, specifically for complex, rare or treatment-resistant cancers. The company offers a range of molecular assays using both genomics and transcriptomics data, and proprietary comprehensive AI therapeutic decision support algorithms. The OmiCure platform provides a deep level of understanding to clinicians, helping them in their informed treatment decision. The SOPHiA DDM™ Platform, which is a cloud-based platform that uses artificial intelligence (AI), will help streamline OmiCure’s tests and algorithms.
“The work we do at OmiCure is personalized and time sensitive, and the ability to use the best towards getting fastest and most accurate results is paramount to the success of our company,” said Thomas Turcat, Founder and COO of OmiCure. “By using the SOPHiA DDM™ Platform we are enhancing our testing and helping to advance the industry’s use of data-driven medicine to create the most personalized treatment plans.”
Since it launched in 2019, OmiCure has been investing in the development of tumor profiling testing tools based on the sequencing and analysis of DNA and RNA. This testing relies on next-generation sequencing (NGS) to help identify key biomarkers. However, NGS can produce a vast dataset. The SOPHiA DDM™ Platform gives access to a fully integrated bioinformatic workflow that helps quickly synthesize the large volume of data that comes with NGS tests. The Platform combines analytical performance with streamlined interpretation of complex genomic variants from comprehensive genomic profiling.
“We work daily at SOPHiA GENETICS to provide technology and solutions that may have the ability to improve care and outcomes,” said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS. “The SOPHiA DDM™ Platform provides highly accurate insights from multiple genomic alterations across a broad panel of genes and provides organizations like OmiCure valuable insights to inform oncologists on treatment options for patients with challenging cancers. We are excited to support OmiCure in advancing its products and expanding the use of data-driven medicine.”
With SOPHiA GENETICS’ global data-sharing network, OmiCure will be able to offer physicians clinically actionable insights from data to help improve patient outcomes worldwide. In addition, the technology will aid OmiCure in creating a more robust in-house database that can be used to help increase its team’s expertise with each test.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on X, LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on X, LinkedIn, Facebook, and Instagram. Where others see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
About OMICURE
OMICURE® SAS is a leading European digital health precision medicine company, that developpes and markets genomic diagnostic oncology products which support physicians with their complex treatment decisions in cancer care. OMICURE®’s technology combines a proprietary advanced, comprehensive analytical xAI platform (explainable Artificial Intelligence platform) that analyzes all clinically relevant cancer biomarkers (DNA, RNA and protein profiles) from both solid and liquid biopsies with its curated cancer treatments knowledge database which continuously learns from cutting-edge, validated, scientific and medical advances. This one-stop-shop analysis and interpretation service gives oncologists actionable results to enable the selection of treatments tailored to the individual patient’s cancer profile.
OMICURE® provides to Anti-Cancer centers, oncologists, and physicians in the world an access to a state-of the-art interpretation to improve their routine oncology-oriented analyses. The xAI platform processes oncology raw NGS and molecular biology data to turn them into clinical insights such as treatment options or clinical trials.
For more information, visit: https://www.omicure.com/
Media Contact:
Kelly Katapodis
[email protected]
